Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FM888
- Development stage
- Phase 2
- Lead developer
- Qingdao Yongzhan Medical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FM888 is an investigational small molecule sodium channel inhibitor developed by Qingdao Yongzhan Pharmaceutical Technology Co., Ltd. It specifically targets the voltage-gated sodium channel Nav1.7 (encoded by the SCN9A gene), which is predominantly expressed in peripheral sensory neurons and is a validated target for the treatment of chronic pain. By inhibiting Nav1.7, FM888 aims to suppress the hyperexcitability of nociceptors that leads to neuropathic pain conditions such as postherpetic neuralgia. The drug is currently being evaluated in Phase 2 clinical trials in China to assess its efficacy and safety profile as an oral analgesic.
02
Targets
SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on FM888.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FM888.